In Europe, use of<unk>  together with strong inhibitors of the liver enzyme CYP2C8, such as gemfibrozil, is contraindicated because it increases concentrations of<unk>  twofold, and its active metabolite 11-fold, potentially leading to more adverse effects.
Selexipag
Vosoritide
Vagisil
Prasugrel
Eteplirsen
Furegrelate
Snoezelen
Tezacaftor